Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Efficacy of repeated low-dose bevacizumab treatment with long-dosing interval for radiation-induced brain necrosis: A case report.

Literature DB >> 28152324

Efficacy of repeated low-dose bevacizumab treatment with long-dosing interval for radiation-induced brain necrosis: A case report.

Xiangying Meng¹, Rugang Zhao², Shikai Wu¹, Ge Shen¹, Lijuan Ding¹, Bing Sun¹, Junliang Wang¹.

Abstract

A 40-year-old Chinese female patient, with radiation-induced brain necrosis after radiosurgery, was treated 6 times with a single dose of 200 mg (3.27 mg/kg) bevacizumab each time, and with an interval of 12-16 weeks between each treatment. Neurological symptoms such as dizziness, fatigue, and headache disappeared after each administration of bevacizumab. The results suggest that repeated bevacizumab treatment using a low-dose and long-dosing interval may significantly alleviate radiation necrosis and its symptoms.

Entities: Chemical Disease Species

Keywords: Bevacizumab; breast carcinoma; metastasisradiation-induced brain necrosis

Mesh：

Substances：

Year: 2017 PMID： 28152324 PMCID： PMC5323015 DOI： 10.1080/15384047.2016.1276127

Source DB: PubMed Journal: Cancer Biol Ther ISSN： 1538-4047 Impact factor: 4.742

18 in total

1. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.

Authors: Victor A Levin; Luc Bidaut; Ping Hou; Ashok J Kumar; Jeffrey S Wefel; B Nebiyou Bekele; Jai Grewal; Sujit Prabhu; Monica Loghin; Mark R Gilbert; Edward F Jackson
Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-01 Impact factor: 7.038

2. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy.

Authors: Tyler J Fraum; Teri N Kreisl; Joohee Sul; Howard A Fine; Fabio M Iwamoto
Journal: J Neurooncol Date: 2011-04-27 Impact factor: 4.130

3. The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles.

Authors: Naosuke Nonoguchi; Shin-Ichi Miyatake; Motoi Fukumoto; Motomasa Furuse; Ryo Hiramatsu; Shinji Kawabata; Toshihiko Kuroiwa; Motomu Tsuji; Manabu Fukumoto; Koji Ono
Journal: J Neurooncol Date: 2011-06-18 Impact factor: 4.130

4. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Authors: Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo
Journal: J Clin Oncol Date: 2005-02-01 Impact factor: 44.544

Review 5. The biology of VEGF and its receptors.

Authors: Napoleone Ferrara; Hans-Peter Gerber; Jennifer LeCouter
Journal: Nat Med Date: 2003-06 Impact factor: 53.440

Review 6. The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review.

Authors: Limor Amit; Irit Ben-Aharon; Liat Vidal; Leonard Leibovici; Salomon Stemmer
Journal: PLoS One Date: 2013-01-22 Impact factor: 3.240

7. Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas.

Authors: Motomasa Furuse; Naosuke Nonoguchi; Shinji Kawabata; Tomo Miyata; Taichiro Toho; Toshihiko Kuroiwa; Shin-Ichi Miyatake
Journal: Radiat Oncol Date: 2015-07-30 Impact factor: 3.481

8. Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery alone or in combination with whole brain radiation therapy for 1-3 cerebral metastases.

Authors: Lars Hendrik Schüttrumpf; Maximilian Niyazi; Silke Birgit Nachbichler; Farkhad Manapov; Nathalie Jansen; Axel Siefert; Claus Belka
Journal: Radiat Oncol Date: 2014-05-02 Impact factor: 3.481

Efficacy of repeated low-dose bevacizumab treatment with long-dosing interval for radiation-induced brain necrosis: A case report.

1. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.

2. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy.

3. The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles.

4. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Review 5. The biology of VEGF and its receptors.

Review 6. The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review.

7. Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas.

8. Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery alone or in combination with whole brain radiation therapy for 1-3 cerebral metastases.

9. Acquired-resistance of bevacizumab treatment for radiation brain necrosis: a case report.

10. Relief Effect of Bevacizumab on Severe Edema Induced by Re-irradiation in Brain Tumor Patients.

1. Single-shot bevacizumab for cerebral radiation injury.

Review 2. Treatment of Radiation-Induced Brain Necrosis.